product pipeline
LifeSprout is developing a suite of regenerative tissue solutions for aesthetic and reconstructive clinical indications. The first product from the pipeline, the Lumina™ dermal filler, has achieved its primary endpoint of correction of moderate-to-severe nasolabial folds (NLF) with good safety. Additional programs in regenerative cell therapy are in earlier stages of development.
Regenerative Cell TherapY
RM-Assisted Lipotransfer
LifeSprout's Regenerative Matrix (RM) can be combined with autologous cells to enable larger volume, more durable restoration with improved cell survival.
Offers solution for numerous therapeutic and reconstructive indications spanning common and orphan conditions.
Impressive preclinical data is leading to a planned proof-of-concept clinical study in 2023.
retention of native tissue architecture
RM-Assisted lipotransfer preserves adipose tissue morphology with improved adipocyte viability compared to the fat graft alone where enlarged vacuoles were observed as shown below at post-injection Day 90 in an animal model.
GREATER NUMBER OF VIABLE ADIPOCYTES
RM-Assisted lipotransfer retains abundant viable adipocytes compared to fat graft alone as evidenced through perilipin staining at Day 30 and Day 90 in an animal model.
Please note: LifeSprout products are currently limited to investigational use only.